Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Day One Biopharmaceuticals is a clinical-stage oncology company focused on developing targeted therapies for pediatric and adult patients with genomically-defined cancers. The company's lead asset, tovorafenib, is a type II RAF kinase inhibitor targeting BRAF-altered tumors, with regulatory submissions underway for pediatric low-grade glioma (pLGG) following positive Phase 2 FIREFLY-1 trial results. The stock trades on binary clinical and regulatory catalysts, with minimal revenue ($0.1B TTM) reflecting early commercialization or milestone payments.
Day One operates a classic biotech model: invest heavily in R&D to advance clinical programs through regulatory approval, then monetize through direct commercialization or partnerships. The 96% gross margin suggests minimal COGS, typical for early-stage biotech with limited product sales. Pricing power will depend on orphan drug status, lack of alternatives for BRAF-altered pLGG, and payer willingness to reimburse precision oncology therapies (typically $150K-$300K+ annually for rare pediatric cancers). Operating leverage is currently negative (-165.7% operating margin) but could inflect sharply post-approval as fixed R&D costs are absorbed by commercial revenue. The company's competitive advantage lies in its type II RAF inhibitor mechanism (potentially superior CNS penetration vs type I inhibitors) and first-mover positioning in genomically-defined pediatric cancers.
FDA regulatory decisions on tovorafenib for pediatric low-grade glioma (PDUFA-type dates, advisory committee outcomes)
Clinical trial data readouts for expansion cohorts (adult glioma, other BRAF-altered solid tumors, combination studies)
Commercial launch metrics post-approval: patient starts, market penetration in ~1,000-1,500 annual US pLGG diagnoses, pricing/reimbursement decisions
Partnership announcements or ex-US licensing deals that validate platform and provide non-dilutive funding
Cash runway updates and financing events (equity raises, debt facilities) given -$100M annual burn rate
Regulatory approval risk: FDA could require additional studies, reject NDA, or impose restrictive labeling that limits commercial opportunity for tovorafenib in pLGG
Reimbursement pressure: Payers increasingly scrutinize ultra-orphan drug pricing, and ICER/cost-effectiveness analyses could limit access despite approval
Clinical trial execution risk: Small patient populations in rare pediatric cancers create enrollment challenges and increase trial timelines/costs
Type I RAF inhibitors (dabrafenib/trametinib combination) already approved for BRAF V600E tumors, creating established standard-of-care competition
Larger oncology players (Novartis, Roche, BMS) developing next-generation RAF/MEK inhibitors with greater resources for clinical development and commercialization
Academic centers and competitors pursuing alternative mechanisms (MEK inhibitors, immunotherapy combinations) for same patient populations
Cash runway risk: With -$100M annual operating cash flow and $1.2B market cap, company likely needs additional financing before profitability, creating dilution risk
Single-asset dependency: Tovorafenib represents substantially all enterprise value; clinical or regulatory failure would be catastrophic
Limited revenue diversification: Minimal current revenue ($0.1B) provides no cushion against development setbacks
low - Oncology drug demand is non-discretionary and largely insulated from GDP fluctuations. Pediatric cancer treatments proceed regardless of economic conditions. However, macro conditions affect: (1) biotech funding environment and ability to raise capital at attractive valuations, (2) M&A appetite from large pharma acquirers, (3) payer budget pressures that could impact reimbursement negotiations.
Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (tovorafenib peak sales likely 2028-2030+). Clinical-stage biotech with no near-term profitability are particularly rate-sensitive as their value is entirely in NPV of future products. Higher rates also increase cost of capital for future financings and reduce attractiveness vs fixed income alternatives for growth investors. However, Day One's strong balance sheet (8.68x current ratio, 0.01 D/E) minimizes direct financing cost impact.
Minimal direct credit exposure given negligible debt (0.01 D/E). However, tighter credit conditions reduce biotech sector liquidity, compress valuations, and make equity raises more dilutive. Investment-grade credit spreads serve as proxy for risk appetite in growth equity markets.
growth - Pure binary clinical/regulatory catalyst play attracting biotech specialists, event-driven funds, and growth investors willing to accept high volatility for asymmetric upside. The 69.8% six-month return and -3.1% one-year return illustrate momentum-driven trading around data catalysts. Not suitable for value or income investors given negative profitability, no dividends, and speculative risk profile. Institutional ownership likely concentrated among healthcare-focused funds with expertise evaluating clinical data and regulatory pathways.
high - Clinical-stage biotech with single lead asset exhibits extreme volatility around binary events (trial readouts, FDA decisions). Recent 34.9% three-month return demonstrates momentum sensitivity. Beta likely >1.5 relative to broader market, with stock capable of ±30-50% moves on material news. Illiquidity in $1.2B market cap name amplifies volatility during sector rotations.
